Sex differences in the pharmacokinetics of pioglitazone in rats

Comparative Biochemistry and Physiology - C Toxicology and Pharmacology

Volumn 136, Issue 1, 2003, Pages 85-94

  Fujita, Yukiyoshi ^a   Yamada, Yasuhiko ^a,c   Kusama, Makiko ^a   Yamauchi, Toshimasa ^b   Kamon, Junji ^b   Kadowaki, Takashi ^b   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

Author keywords

Active metabolites; Adipose tissue; Concentration; Peroxisome proliferator activated receptor (PPAR ); Pharmacokinetics; Pioglitazone; Rats; Sex difference

Indexed keywords

DRUG METABOLITE; PIOGLITAZONE;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG METABOLISM; NONHUMAN; PRIORITY JOURNAL; RAT; SEX DIFFERENCE; STATISTICAL SIGNIFICANCE;

EID: 1542714421     PISSN: 15320456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1532-0456(03)00194-7     Document Type: Article

References (32)

1. Adams M., Montague C.T., Prins J.B., Holder J.C., Smith S.A., Sanders L., et al. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. 100:1997;3149-3153.
2. Akazawa S., Sun F., Ito M., Kawasaki E., Eguchi K. Efficacy of troglitazone on body fat distribution in type 2 diabetes. Diabetes Care. 23:2000;1067-1071.
3. Anderson L.A. The effects of androgens and estrogens on preadipocyte proliferation in human adipose tissue: influence of gender and sidte. J. Clin. Endocrinol. Metab. 86:2001;5045-5051.
4. Baldwin S.J., Clarke S.E., Chenery R.J. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br. J. Clin. Pharmacol. 48:1999;424-432.
5. Cox P.J., Ryan D.A., Hollis F.J., Harris A.M., Miller A.K., Vousden M., et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab. Dispos. 28:2000;772-780.
6. Dieudonne M.N., Pecquery R., Boumediene A., Leneveu M.C., Giudicelli Y. Androgen receptors in human preadipocytes and adipocytes: regional specificities and regulation by sex steroids. Am. J. Physiol. 274:1998;C1645-1652.
7. Dieudonne M.N., Pecquery R., Leneveu M.C., Giudicelli Y. Opposite effects of androgens and estrogens on adipogenesis in rat preadipocytes: evidence for sex and site-related specificities and possible involvement of insulin-like growth factor 1 receptor and peroxisome proliferator-activated receptor gamma2. Endocrinology. 141:2000;649-656.
8. Hanefeld M. Pharmacokinetics and clinical efficacy of pioglitazone. Int. J. Clin. Pract. (Suppl.):2001;19-25.
9. Ikeda T., Fujiyama K. The effect of pioglitazone on glucose metabolism and insulin uptake in the perfused liver and hindquarter of high-fructose-fed rats. Metabolism. 47:1998;1152-1155.
10. Imamura Y., Kaneko M., Takada H., Otagiri M., Shimada H., Akita H. Sex-dependent pharmacokinetics of S(-)-hydroxyhexamide, a pharmacologically active metabolite of acetohexamide, in rats. Comp. Biochem. Physiol. C. 133:2002;587-592.
11. Kato R., Yamazoe Y. Sex-specific cytochrome P450 as a cause of sex- and species-related differences in drug toxicity. Toxicol. Lett. 64-65:1992;661-667.
12. Katsuki A., Sumida Y., Murata K., Furuta M., Araki-Sasaki R., Tsuchihashi K. Troglitazone reduces plasma levels of tumour necrosis factor-alpha in obese patients with type 2 diabetes. Diabetes Obesity Metab. 2:2000;189-191.
13. Kiyota Y., Kondo T., Maeshiba Y., Hashimoto A., Yamashita K., Yoshimura Y., et al. Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneim.-Forsch./Drug Res. 47:1997;22-28.
14. Krieter P.A., Colletti A.E., Doss G.A., Miller R.R. Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab. Dispos. 22:1994;625-630.
15. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 270:1995;12953-12956.
16. Lowell B.B. PPARgamma: an essential regulator of adipogenesis and modulator of fat cell function. Cell. 99:1999;239-242.
17. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., Tanayama S. Disposition of AD-4833 (HCl), a new antidiabetic agent, in animals. Jpn. Pharmacol. Ther. 24:1996;2597-2617.
18. Maeshiba Y., Kiyota Y., Yamashita K., Yoshimura Y., Motohashi M., Tanayama S. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys. Arzneim.-Forsch./Drug Res. 47:1997;29-35.
19. Malinowski J.M., Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin. Ther. 22:2000;1151-1168. Discussion 1149-1150.
20. Miyazaki Y., Mahankali A., Matsuda M., Glass L., Mahankali S., Ferrannini E., et al. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. Diabetes Care. 24:2001;710-719.
21. Mori Y., Murakawa Y., Okada K., Horikoshi H., Yokoyama J., Tajima N., et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care. 22:1999;908-912.
22. Mugford C.A., Kedderis G.L. Sex-dependent metabolism of xenobiotics. Drug Metab. Rev. 30:1998;441-498.
23. Murase K., Odaka H., Suzuki M., Tayuki N., Ikeda H. Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia. 41:1998;257-264.
24. Okuno A., Tamemoto H., Tobe K., Ueki K., Mori Y., Iwamoto K., et al. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J. Clin. Invest. 101:1998;1354-1361.
25. Sohda T., Ikeda H., Meguro K. Studies on antidiabetic agents. XII. Synthesis and activity of the metabolites of (+/-)-5(-)[p(-)[2-(5-ethyl-2- pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione (pioglitazone). Chem. Pharm. Bull. 43:1995;2168-2172.
26. Spiegelman B.M., Flier J.S. Adipogenesis and obesity: rounding out the big picture. Cell. 87:1996;377-389.
27. Tanis S.P., Parker T.T., Colca J.R., Fisher R.M., Kletzein R.F. Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. J. Med. Chem. 39:1996;5053-5063.
28. Yamaoka T., Nakagawa T., Uno T. Statical moments in pharmacokinetics. J. Pharmacokin. Biopharm. 1978;547-558.
29. Yamashita K., Murakami H., Okuda T., Motohashi M. High-performance liquid chromatographic determination of pioglitazone and its metabolites in human serum and urine. J. Chromatogr. B Biomed. Appl. 677:1996;141-146.
30. Yamauchi T., Kamon J., Waki H., Murakami K., Motojima K., Komeda K., et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J. Biol. Chem. 276:2001;41245-41254.
31. Yang W.S., Jeng C.Y., Wu T.J., Tanaka S., Funahashi T., Matsuzawa Y., et al. Synthetic peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care. 25:2002;376-380.
32. Ye J.M., Iglesias M.A., Watson D.G., Ellis B., Wood L., Jensen P.B., et al. PPARalpha/gamma ragaglitazar eliminates fatty liver and enhances insulin action in fat-fed rats in the absence of hepatomegaly. Am. J. Physiol. 284:2003;E531-540.